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INTRODUCTION 
 
 The health problems associated with  smoking tobacco  are well 
known  which include both the acute symptoms such as cough, 
dyspnea,throat irritation,frequent lower respiratory tract infections and 
the increased risk of developing chronic and serious medical conditions 
such as bronchogenic carcinoma, heart disease , exacerbation of chronic 
obstructive pulmonary diseases like chronic 
bronchitis,bronchiectasis,bronchial asthma and  emphysema ,aggravation 
of thrombo-embolic phenomena like stroke,myocardial 
infarction,Thrombo-angitis Obliterans etc. Apart from the medical 
complications involving the respiratory tract, people who smoke 
cigarettes tend more frequently to have oral, nose, and throat cancer due 
to inhalation of the smoke than it is among the nonsmokers of the same 
age group.  
                Patients diagnosed as  schizophrenia are much more likely to 
smoke , the prevalence being approximately 70 percent as against 30 
percent in the general adult population . Earlier studies on this proposed 
that the higher rates of smoking and use of smokeless tobacco among 
schizophrenic patients might be a reflection of their effort to subjectively 
remediate cognitive dysfunction by themselves1 .Many different 
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explanations have been proposed for this high prevalence,however a 
matrix of causes have been implicated namely  neurological,  behavioral, 
psychological and environmental factors. 
            Smoking being a very common pattern of behaviour among 
patients with schizophrenia is also an important modifiable risk factor 
that contributes to medical mortality. It has been found that 
Schizophrenic patients also tend to be heavier smokers. In the Clinical 
Antipsychotic Trials of Intervention Effectiveness(CATIE)2 study a total 
of  68 percent of schizophrenia patients were nicotine dependent. 
           Both the morbidity and the mortality caused by cardiovascular 
diseases are found to be much higher in people with schizophrenia 
irrespective of their treatment status than in the general population3.. 
Dyslipidaemia is an established risk factor for cardiovascular disease 
along with hypertension, diabetes,  obesity,  smoking and a sedentary 
lifestyle. The majority of patients with schizophrenia have several of 
these risk factors and can be considered to be having a higher propensity 
to  develop cardiovascular diseases. 
              The most important cardiovascular cause  of mortality in 
schizophrenic patients is coronary heart disease 4. In a study by Goff et al 
in 2005 comparing the risk of cardiovascular risk among those patients 
from  the follow up of CATIE study and  controls it was found that 
schizophrenic individuals  had a greater  ten year risk of developing 
3 
 
cardiovascular diseases in  comparison to the  general population in 
respect for both sexes : male schizophrenics developing at a rate of  9.4% 
vs  a rate of  7.0% in the  general population males  and female 
schizophrenics at a rate of 6.3% vs a rate of 4.2% in the general 
population females 5 .Moreover one other  recent report notes that the 
mortality ratio for cardiovascular death is  about  3 times  the general 
population ratio  in  schizophrenic patients.6 
           Apart from the high morbidity and mortality in persons who 
smoke, combined with  a high propensity to develop  metabolic syndrome 
in schizophrenic patients on antipsychotics for a prolonged duration, 
these patients are at a very high risk to develop cardiac and lung 
diseases.Though there have been numerous studies in the west that 
looked into the medical co-morbidities in schizophrenic patients there is a 
huge paucity in our Indian studies. 
           The World Health Organisation proposes that about 13% of all 
deaths among Indians by the year 2020 would be linked to the association 
between  the use of tobacco and infections like  tuberculosis, lung cancer, 
other chronic lung diseases and  cardiovascular diseases .Thus we see that 
the human health and economical burden of using tobacco for  a densely 
populated country like India with highly effective marketing strategies for 
tobacco related products are  strikingly high.This underscores the need 
for  immediate attention  to curb the tobacco related harmful 
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consequences  in people of all age groups especially among the more 
susceptible mentally ill . 
               Further smoking being the most commonly used,cheap,freely 
available ,less stigmatizing substance of abuse may serve as a gateway for 
the onset of  a huge array of substance abuse.The gateway drug theory 
also known as gateway effect  /gateway theory/ gateway hypothesis    
states that persons who start using   less deleterious drug of dependance  
run a high future risk of using more dangerous hard drugs and/or crime 
.This theory has often been used to explain polysubstance abuse  of many  
drugs including   tobacco, alcohol and cannabis.This very much applies to 
the mentally ill population who are at the greatest risk for substance 
dependance. 
 
Rationale for this study: 
            It is necessary to address this  comorbidity of substance use in  
schizophrenic patients because of its  association with poorer clinical and 
social outcomes and  it significantly  contributes to their morbidity and 
mortality . Overall, substance-use disorders  are a harbinger of  a worser 
course and outcome  of all severe psychiatric illnesses  by causing more 
frequent  relapses ,the higher need for hospitalizations, poor psychosocial 
functioning even after control of active symptoms and more  of legal, 
health and housing  problems. 
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          There have been studies conducted in the United states,the Spanish 
population and in Chinese population.However such a study of this kind 
has not been carried out in our Indian population.This prompted us to 
perform this study to look into the extent of nicotine dependence among 
our population and to see its effect on the positive and negative symptoms 
of schizophrenia, its association with  antipsychotic dosing in these 
patients and its effect on medication induced movement disorders.  
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REVIEW OF LITERATURE 
HISTORY OF NICOTINE 
 In 1512, the tobacco plant was introduced into Portugal, where it 
was used first by sniffing powdered leaves of the plant to relieve migraine 
and until 1559 their use in Europe has been limited to in this country .In 
1560 Jean Nicot introduced tobacco as a wedding gift for the royal family 
at Paris. Later  in 1570, the tobacco plant was officially named after him 
as  Nicotiana tabacum. In 1828, nicotine was first isolated from nicotinic 
acid and was known  as niacin or vitamin B .It was first synthesized in the 
laboratory in 19047. 
FORMS OF SMOKING TOBACCO DEPENDANCE 
 Cigarettes or cigars, hookah tobacco,hand-rolled 
tobacco,snuff,gutka,chewing tobacco leads on to health problems, which 
may be  ultimately fatal .There are various methods of smoking8, which 
include many varieties of cigarettes, bidis, like, Hookah, Dhumti, reverse 
chutta, Chillum, cigars, cheroots and many flavors of chewing gum as 
Gutkha Khaini, Zarda, Gudhaku, paan (with smoking) Gul, Mawa, Mishri 
and some other forms as well. 
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Beedi 
 In India beedi is the most commonly used form of tobacco . India  
utilizes about  thirty-five  percentage  of its  tobacco  for manufacturing 
beedi.  
 Beedi are flakes of dried tobacco which is  rolled in a dried, 
rectangular piece of tendu leaves. 
Cigarettes  
 These are the second most commonly used form of tobacco in 
India after beedis.It is used more frequently by the  affordable population. 
Cigars 
 Cigars are  fermented tobacco cured by air,  often manufactured  in 
factories and are usually  more expensive than beeidis and cigarretes. 
Cigar smoke is most used in   urban settings in north India  .It is rarely 
used these days in south India. 
Chuttas and cheroots: 
  Chuttas which is  a cylinder homemade  from tobacco leaves. In 
India a huge quantity of chuttas are made every year as much as 3000 
million units .Another mode of smoking chutta namely Reverse chutta 
smoking is being prevalent in some of the  coastal areas of Tamil Nadu 
,Andhra Pradesh and Orissa. 
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Pipe 
 Pipe smoking is an older  form of tobacco use where they use small 
wooden rods or pipes ,long metal rod or other material. 
Dhumti 
 It is another form of smoking tobacco but unlike beedi and chuttas 
,dhumtis cannot be obtained  from the  routine suppliers of cigarettes, but 
are prepared  by the  consumers themselves. It is made by rolling cigar 
tobacco leaves  in the sheets from another plant. 
Hookah 
 The hookah is a type of pipe in India, where tobacco is smoked 
through water before inhalation. 
Chillum: 
 It is a clay pipe filled with tobacco.It is used exclusively by 
males.Chillum was in use in India even before the use of tobacco for 
smoking other drugs like  opium etc. 
 
FORMS OF SMOKELESS TOBACCO DEPENDANCE  
 Most practices of chewing tobacco are more common in the north 
and northeastern India. "Smokeless tobacco" is the type of  tobacco use in  
which  tobacco is consumed without heating or burning while  it is  used9. 
It is either used orally or nasally. For nasal use the dry snuff which is  
fine tobacco powder layer mixed with aromatics is used. The other 
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methods of taking tobacco are by means of  sucking,chewing  and as 
applications of  tobacco preparations on teeth and gums.  
Paan  is a form of betel with tobacco.Betel leaves contain volatile oils 
such as terpenes  and eugenol ,small amounts of sugar, starch, tannin 
,nitrates etc.Zarda  are commercially manufactured varieties are often 
used as ingredients in paan. 
Paan masala 
 Paan masala is a widely marketed commercial preparation 
containing  areca nut, slaked lime, catechu and spices with or without 
powder tobacco.Paan masala is very popular in urban areas and is also 
fast becoming popular in rural areas. Other Tobacco, areca nut and slaked 
lime preparations include Mainpuri tobacco,Mawa 
Tobacco and slaked lime (Khaini):it is  a mixture of dried tobacco and 
slaked lime and is widely used in Maharashtra and also in several states 
in North India 
Chewing tobacco 
Snus 
 This  snuff called snus is available in teabaglike sachets. Several 
preparations of smokeless tobacco as Mishri, gudhaku, bajjar and creamy 
snuff are  first and foremost used as a powder to clean the teeth and gums. 
However in due course it turned out to be substances of dependance. 
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Gul is a pyrolysed tobacco product. Bajjar is a  dry snuff.Traditionally 
few tobacco based toothpastes were introduced into the market , but after 
passing a law banning smoking in dental care products, the list of tobacco 
as an ingredient was stopped. 
Gudhaku is made of  a paste of tobacco and molasses.  
Nicotine gum 
 Nicotine chewing gum with nicotine to 2% (good - kha) was 
introduced as an aid to smoking cessation. For chewers, it is in gutka 
flavor and smokers, mint flavor. 
 With reference to previous studies done in India , the dependency 
ratio for beedi cigarettes and chewing tobacco was 56%, 30% and 67%, 
respectively 10. The rates of combined  smoking  and smokeless/chewing 
tobacco use was 45% . This  value is a bit higher than that obtained by 
another Chennai based study done by Srinivasan(2002) which quotes  a 
prevalence of 31.6%  and even higher than that (33%) for the Indian 
males of the general population11. 
PATTERNS OF NICOTINE USE: 
 Most smokers begin their habit in their teens.The habit is mainly 
acquired through social contacts and the risk is increased if the family 
members  and friends also smoke. Smokeless tobacco in the form of snuff 
or chewing tobacco forms a less frequent but sizeable portion of tobacco 
use. By making harder puffs, deeper or more frequent puffs they are able 
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to obtain significant  amounts of nicotine from fewer cigarettes or from 
low nicotine cigarettes. Patterns may also depend on social factors. 
Suppression of smoking in forbidden areas like hospitals, religious 
places, aircrafts etc. forces smokers to alter their pattern of intake to 
accommodate the periods of deprivation. After a period of experimental 
smoking person enters a period of initiation when he smokes less than 
one cigarette per week. During experimental smoking peers often provide 
social reinforcement. Smoking for the adolescents serves as a means of 
expressing an image of toughness,  precocity and sociability. 
Experimental inhalation is followed by habituation in which the person 
smokes atleast one cigarette per week and acquires the skill of inhalation 
and regulation of the dose of nicotine. With habituation the consumption 
may increase to a pack or more per day. Habituation progresses to the 
development of dependance. 
PHARMACOLOGY OF NICOTINE: 
 Nicotine  is  both a water and lipid soluble weak base .It  has an  
index of ionization about 8.0.The nicotine which is  present in the slightly  
alkaline smoke of cigars, pipes, snuff and chewing tobacco  gets  readily 
absorbed across the  mucosal membranes of the mouth and nose 12. 
However the more commonly used cigarette smoke is mildly acidic and is 
not well absorbed from the mouth and  it has to be inhaled for effective 
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absorption. Thus the absorption of nicotine  through the mucous 
membrane occurs in a highly pH dependent  fashion . 
PHARMACOKINETICS OF NICOTINE: 
 The cigarette tobacco is the most toxic and addictive widely used 
vehicle for delivery of  nicotine . Nicotine  present in cigarette smoke is 
suspended on minute particles of “tar” after getting  distilled at the tip of 
a burning cigarette .This tar is absorbed quickly from the lung almost 
with the efficiency of IV administration.It reaches the brain within 0.8 
seconds after inhalation. Cigarettes are  also the source of carbon 
monoxide(CO) and many other toxic  pyrolysis products. The  nicotine     
absorbed in the  lung alveoli  is  finally   concentrated in the pulmonary 
veins and then  pumped by the left ventricle of the heart throughout the 
body. 
 Nicotine  gets  absorbed from the respiratory tract, buccal 
membranes, and skin. Being    a relatively strong base, the absorption of 
nicotine from the stomach is low whereas the absorption at the  intestinal 
level is much  more efficient. 
 An  average cigarette contains  approximately 6–11 mg nicotine . 
The smoker who smokes a pack per day thus obtains 20-40 mg of 
nicotine each day in total .The peak plasma concentrations of nicotine in 
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the plasma after a cigarette is smoked are typically 25-50 ng/ml. The half 
life is half  an hour to 2 hours.   The nicotine in chewing tobacco on the 
other hand   because  of its slower absorption than inhaled nicotine, tends 
to have  a longer duration of effect. Further the  nicotine bioavailability  
can be  increased  according to the technique and  the intensity of puffing 
of the smoker. Regular smokers are able to very often without conscious 
knowledge or effort, calibrate the plasma concentrations by regulating the 
puff volume, inter-puff interval and the amount of smoke inhaled. This 
has been more so in the  schizophrenic smokers in whom  it is raised  as 
much as threefold since these patients  by the very nature of their disease   
tend to take longer and deeper puffs and thus extract very high quantities 
of nicotine from a single cigarette.Hence nicotine and tar intake cannot be 
determined accurately by the amount smoked since the dose is affected 
by the manner of smoking. The rate of nicotine absorption is rapid for 
cigarettes. However the nicotine level in the blood   falls quickly since 
nearly 50% of it gets redistributed within twenty minutes of the last puff 
of cigarette. 
METABOLISM : 
 Almost   80–90% of nicotine remains in an  altered form in the 
body, mainly in the liver , kidney and lung and less than a 5% is excreted 
in the urine in an unchanged form . The major initial nicotine metabolite 
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is cotinine, which is  about  one-twentieth to  one-hundredth as potent as 
nicotine 13. Cotinine has been   used as a  marker for  nicotine intake 
because it has a half life of half hour to  20 hours  and   can be  easily 
measured in blood, urine, or saliva. 
              The  harmful  Carbon monoxide (CO)  coming from the smoke 
of the cigarette  with a half-life of  4-7 hours gets eliminated from the 
lung and it is a reliable  and measurable function of respiration rate. 
Hence by   measuring the expired air Carbon monoxide(CO) or 
Carboxyhaemoglobin(COHb) we can estmate the time lag  of recent 
cigarette smoke exposure . 
TOLERANCE 
 Tolerance  occurs to an array  of  behavioral, physiological and 
subjective effects of nicotine. The   mechanisms that underlie  nicotine 
tolerance are  decreased responsiveness to the drug ,increased number of 
nicotine receptors and some degree of increased metabolism . It has been 
found that cigarette smokers lose a sizeable degree of tolerance while 
they sleep each day which they attempt to  regain  upon resumption of 
smoking. A single nicotine exposure has the propensity to cause  
tachyphylaxis14  which may be defined as a short-lived tolerance to the  
psychoactive, cardiovascular, and other effects of nicotine. 
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WITHDRAWAL SYNDROME: 
 It includes mood changes , difficulty concentrating, restlessness, 
insomnia, decreased heart rate  and weight gain . The insomnia may be 
characterized by  increased awakenings and intense dreaming. Post 
nicotine cessation weight gain may be explained by the  increased eating 
and the loss of nicotine stimulation of metabolism. Craving is common 
and increased coughing, altered bowel movements in the form of 
constipation, oral  ulcers  and decreased performance on tests of vigilance 
tasks can occur.  
             This withdrawal  syndrome is typically most severe for 
abstinence from cigarettes, intermediate for  abstinence from smokeless 
tobacco, and least severe with abstinence from nicotine-replacement 
products. The   withdrawal symptoms  may vary for a duration of  1 to 3 
days and may even  last up to 2 to 3 weeks. The nicotine  craving and 
weight gain can persist for  even 6 months or more. 
PHARMACODYNAMICS: 
 Nicotine causes release of catecholamines in the central nervous 
system (CNS) as well as of serotonin,ADH,corticotrophin and growth 
hormone.On the cardiovascular system ,the effects are those of 
sympathetic autonomic stimulation.There is vasoconstriction in the skin 
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and vasodilatation in the muscles,tachycardia and a rise in blood pressure 
of about 15mmHg systolic and 10mm Hg diastolic and increased plasma 
noradrenalin. Ventricular extrasystoles may occur and cardiac output 
,work and oxygen consumption increase. Nicotine increases platelet 
adhesiveness ,an effect  that may be clinically significant in atheroma and 
thrombosis. Nicotine increases metabolic rate and hence stopping of 
smoking may lead to weight gain in some individuals. Tolerance 
develops to some of  the effects of nicotine taken repeatedly over few 
hours. 
    Nicotine is an agonist to receptors at the ends of peripheral 
cholinergic nerves whose cell bodies lie in the central nervous system  i.e. 
it acts at the autonomic ganglia and at the voluntary neuromuscular 
junction. Higher doses paralyse the same points. The CNS is stimulated 
including the vomiting centre and tremors and convulsions may occur 
.However as with peripheral actions depression follows stimulation. 
     Cigarette smoke being  powerful hepatic enzyme inducer rapidly 
metabolises many of the drugs which are normally metabolized by the 
liver.The implication of this is that patients may require  a much higher 
doses of many  drugs for treating their symptoms   when they smoke 
heavily  than that needed for the  nonsmokers to obtain similar plasma 
levels. Apart from nicotine having  pharmacodynamic effects, non - 
nicotine chemicals in tobacco smoke  activate the cytochrome P450 
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enzyme systems, thereby decreasing the plasma levels of those  
medications that are normally metabolized in the liver.  This explains that  
when a person stops smoking the concentrations of many of these 
medications increase which might precipitate many of the  dose related 
adverse effects. Many of these medications being psychiatric medicines  
the increase in concentration can be clinically significant; for example, 
haloperidol , clozapine and fluvoxamine concentrations increase 30 to 
40 percent with abstinence. 
NEUROBIOLOGY OF NICOTINE ADDICTION 
 Nicotine diffuses  into the  brain tissue and gets  bound to the  
nicotinic acetylcholine receptors  (nAChRs), which are ligand-gated ion 
channels.The Nicotinic acetylcholine receptor  complex is composed of 5 
subunits which  is found in both the peripheral and central nervous 
systems. The most abundant receptor subtypes present in human  brains  
are α4 β 2, α 3 β 4, and α7 . The α 4 β 2 receptor subtype is the most  
predominant subtype among the three  and is believed to be the main 
receptor mediating nicotine dependence. 
                 The α 4 subunit  is the receptor that determines the individual’s 
sensitivity to nicotine. The  α3 β 4 and the α 7 homomeric receptor 
subtypes are said to mediate the cardiovascular effects of nicotine. The α 
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7 subtype has been implicated  in rapid synaptic transmission and is 
found to  play a role in sensory gating and learning. 
TOBACCO USE: 
 Tobacco use is the  habitual use of  any of  the tobacco plant leaf 
and its products. The majority of persons with nicotine dependance use 
tobacco in the smoking form by using beedis, cigarettes, pipes, and 
cigars. Smokeless tobacco is the use  of tobacco products by way of  
sniffing , sucking or chewing. Chewing tobacco the person places a  
portion of the tobacco between his cheek and gum or upper lip teeth  fro 
sometime and then chews it. All the tobacco products  contain the highly 
addictive psychoactive ingredient  nicotine. 
        Updated  studies show that there is a 30 to 80%  higher  total 
mortality in cigarette smokers when compared to nonsmokers. This 
increased mortality  depends on the age at which the person begins to 
start smoking and on the average  number of cigarettes that the person  
smokes in a  day. Since  schizophrenic patients have a much  heavier 
abuse of tobacco, there is an increased  risk for mortality in  these 
patients. Further it has  also  been  found from various studies that people 
aged 35–54 years who smoke more than  one  pack per day had an 
increase in the  absolute mortality risk   by  170% as compared to the non 
smokers. 15 
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        Early age at onset of smoking and using  cigarettes which are  higher 
in tar increases the risk of these diseases.The environmental tobacco 
smoke or secondhand smoke also  causes  varied adverse health effects in 
people of all ages due to the effects of passive smoking. 
                     The cigarettes sold in underdeveloped countries  tend to 
have higher tar content  and are less likely to be filtered thus potentially 
increases the  vulnerability to tobacco-related disease in these regions. 
Among the 4000 compounds that has been identified in cigarette smoke, 
constituents like  tar, carbon dioxide, nitrous oxides, and nicotine are 
responsible for the major health hazards of smoking.  
  The smokeless tobacco also carries its own risk by its contents being 
rich in specific carcinogenic N-nitrosamines which are produced from 
nicotine, nornicotine, and anatabine during the curing and processing of 
the smokeless tobacco.   
GLOBAL BURDEN OF TOBACCO 
 Almost  22% of the world’s population aged  more than 15 years  
are smokers.Among the  1.22 billion smokers in the world, 47% are  men 
and 12% are women. In the developing countries the rates range from 
about 48% in  men and about 7% in women, which might be because 
smoking has spread there only recently. Among  the 1.22 billion smokers, 
1 billion of them live in developing or transitional economies. It is said 
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that nearly 80% of the world's one billion smokers live in the low- and 
middle-income countries. 
 Globally 12% of all deaths among adults aged 30 years and over 
were attributed to tobacco.Tobacco kills  almost one person every six 
seconds. It has been speculated that a third to half of all people who use 
it, die on average 15 years  prematurely. Today, tobacco  is said to use 
cause 1 in 10 deaths among adults worldwide –which amounts to more 
than five million people a year. And it is predicted that by 2030, unless 
urgent action is taken, tobacco’s annual death toll is estimated to rise to 
more than eight million. 16 
 And according to the  World Health Organization (WHO), tobacco 
kills more people annually than does the problematic  diseases like 
alcohol, AIDS, other addictions (drugs) and accidents put together. 
TOBACCO BURDEN IN INDIA 
 There are approximately 120 million smokers in India, about 37 
percent of all men and 5 percent of all women between the ages of 30 and 
69. According to the study published in the New England Journal of 
Medicine17, more than 50 percent of the tobacco-related deaths in India 
occur among illiterate men or women, and 80 percent of those people 
reside in rural India.  
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The WHO reports suggest at least one form of tobacco is used by  65% of 
all Indian men . The usage statistics  for women  differed grossly  from as 
high as 67% in Andhra Pradesh to as low as 15% in rural Gujarat . The 
overall prevalence for bidi and cigarette smoking is 3% .It has been 
reported that  fully one third of all women use at least one form of 
tobacco and  used smokeless form in most instances18. About   58 % of 
women use tobacco in Mumbai solely in the smokeless form. 
 According to the  National Sample Survey (NSS) in India, 15% 
consume cigarettes, 54% of tobacco consumers consume bidi, and 30% 
consume different chewing tobacco products. 
 It has been estimated  that only 20% of the total tobacco consumed 
in India is in the form of cigarettes, whereas  40% of the tobacco used  is 
in the form of bidis and the remaining 40% is consumed as chewing 
tobacco, pan masala, snuff, masheri ,gutkha and tobacco toothpaste. 
These products contain lime, catechu, putrefied tobacco, paraffin, areca 
nut and even  many carcinogenic agents. 
 India is the second largest producer of tobacco in the world and  
further it ranks fourth in total tobacco consumption. The  important 
reason implicated for the high  economic burden in India is because of the 
availability of the various forms of tobacco.  
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The sex specific ratio of tobacco users in India  
Type of tobacco 
users 
Male 
(%) 
Female  
(%) 
Tobacco users 46.5 13.8 
Smokers 29.3 2.4 
Chewers 28.1 12.0 
 
EPIDEMIOLOGY OF SMOKING IN PSYCHIATRIC PATIENTS 
Comorbid Drug Abuse and Mental illness: 
 The lifetime prevalence of substance use disorder (abuse or 
dependence) including alcohol in patients with schizophrenia ranges from 
10% to 60% 19.The Epidemiologic Catchment Area (ECA)study reported 
that 46% of patients with schizophrenia have some serious health 
problem with substance use during their lifetime compared with 16% of 
that in the general population . 20 The  nicotine use rates in these patients  
range from 58% to 90% 21. 
 Of illicit substances, patients with schizophrenia preferentially use 
cannabis 22 , although cocaine abuse is also common, especially in the 
inner cities23. Similar to the general population, men are 
disproportionately represented among patients who use substances.  
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Smoking and Depression: 
 Much evidence supports an association between depressive 
symptomatology and smoking. It has been found in few studies that 
smokers exhibit higher rates of depression than the  nonsmokers24  and 
that the  depressed persons experience greater difficulty quitting as 
compared to nondepressed, smokers25. Even subclinical levels of 
depression are associated with decreased latency to first cigarette 
following a quit attempt26.  
Smoking and Other Chemical Dependence 
 Rates of smoking among abusers of other drugs are higher than 
those in the general population, with estimates ranging from 75% to 90% 
27. Comorbidity is associated with increased health problems 28, as well as 
smoking and smoking cessation behaviors. Alcoholic smokers often tend 
to smoke more heavily and are found to experience lesser success in 
achieving abstinence than their nonalcoholic counterparts 29. 
NICOTINE DEPENDANCE AND SCHIZOPHRENIA 
 Regarding the association between cigarette smoking and 
schizophrenia various facts  have been proposed and the findings include 
the following: 
1. The rate of smoking  is at least 2 to 3 times higher in schizophrenia  
patients  that in the general population 
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2. Schizophrenic patients who smoke, do so  at heavier rates than that 
in the general population 
3. Most of the smoking schizophrenic patients start smoking in their 
teens and many of them did so before the illness begins 
 Further few researchers have explained that nicotine dependance in 
schizophrenic patients is a method invented by patients themselves to 
"Self-medicate"  their illness.The various neurocognitive dysfunctions of 
schizophrenia like attention ,cognition and information processing 
deficits are the prime symptoms that are being targeted by this nicotine 
dependance . The reasons offered include: 
1. Disease aspects  leading more patients to smoke 
2. Smoking has been thought of to be  an  independent  
aetiological factor in schizophrenia rather than mere co-
occurrence. 
3. The possibility of genetic and environmental factors that 
predispose to both smoking and the disease. 
 Few authors have explained that the higher frequency of current 
smoking schizophrenic  patients could be  a summation  of a  higher 
initiation rate added on to a  lower rate of quitting smoking. And further 
since most patients with schizophrenia begin to smoke before the  onset 
of the schizophrenic  illness, it has been postulated that  persons prone to 
develop  schizophrenia had a high vulnerability to starting smoking 
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.Other authors like Freedman et al. (1997) have described the presence of 
a neurophysiological abnormality that was genetically determined in 
patients with schizophrenia and their relatives, which was thought to be 
corrected atleast temporarily by a high peak of nicotine.  
             Based on exposure to tobacco, patients with schizophrenia are 
most vulnerable to adverse health consequences. Surprisingly, despite the 
high exposure to tobacco smoke, a number of reports suggest a lower rate 
of lung cancer and other malignancies in schizophrenic patients than in 
the population at large 30 . On the other hand, a study by Lichtermann31   
based on Finland’s National Hospital Discharge and Disability Pension 
registers linked to the Finnish Cancer Registry, showed a higher rate of 
cancer (particularly of the lung) among schizophrenic individuals than in 
the population at large. The Finnish study also examined rates of illness 
among first-degree relatives of  schizophrenic patients and found a lower-
than-expected risk of cancer. 
            Lichtermann hypothesizes that access to cigarettes (eg,smoking 
policies on psychiatric units), rates of institutionalization, access to 
medication, and population genetic variations may all contribute to  
differences with other published studies. Apart from cancer risk, 
individuals with schizophrenia suffer higher death rates from 
cardiovascular and respiratory disease  32. Therefore  the weight of 
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evidence points toward increased health risks from smoking as a result of 
increased smoking rates in schizophrenia. 
             One Indian study  that examined the non-biological factors 
influencing the prevalence of smoking   in   schizophrenia and stated that 
the rates of smoking in schizophrenic patients   was higher  than in  
patients diagnosed to have  major affective disorders and other  non-
psychotic disorders and the reasons cited include family imposed 
restrictions on smoking  and the lack of economic independence in these 
patients.They concluded with remarks of the need to consider the 
influence culture and social practices could have upon the behaviour. 
ROLE OF SMOKING IN SCHIZOPHRENIA:SYMPTOM 
CORRELATES 
 Smoking has been suggested to be  a marker of greater severity of  
schizophrenic illness .The correlations between fagerstorms nicotine 
dependance scores and the total of the negative symptom scores in 
schizophrenia has been found to be a significantly positive one, with no 
signficant associations with positive symptoms however 33. Further, 
symptoms like impairement in attention, thinking, impulse control and 
orientation, and the scores on SANS- negative symptom subscales like 
blunted affect, social withdrawal ,stereotyped thinking and difficulty in 
abstract thinking , has been positively correlated with the severity of 
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nicotine dependence.Few contrary studies stated that smoking 
schizophrenia patients display less negative symptoms compared to non 
smoking schizophrenia patients 34. 
 Also, smokers may have higher scores on brief psychiatric  rating 
scale due to more severe symptoms.It may also be that, patients with 
schizophrenia smoke with nicotine inorder to  self medicate their disease 
,where nicotine may help by regulating a dysfunctional  mesolimbic 
dopamine pathway. 
 Positive and negative  symptoms may be alleviated due to the 
supposedly nicotine caused increase of dopamine release in pre frontal 
cortex.There has been reports of psychotic symptoms worsening on 
nicotine withdrawal. There are reports of enhancement of cognitive 
performance on nicotine administration. 
 However, smoking schizophrenia patients, in general report the 
same reasons as other smokers, and offer reasons like  the need to feel 
“addicted”, “relaxed” and “to calm down” with only  a meager 17%  of 
them reporting improvement of psychotic symptoms on smoking. This is 
a point against the self medication hypothesis put forward by few 
researchers. 
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In one of the most recent studies conducted in India  ,association has been 
found between higher  positive  symptom scores and  tobacco use, with 
however  no significant differences in cognitive measure among nicotine 
non dependant and  dependant patients. 35 
 SENSORY GATING AND PREPULSE INHIBITION IN SCHIZOPHRENIA  
Sensory Gating (P50) Deficit 
 Sensory gating refers to the centrally mediated inhibition of 
neuronal response to a redundant sensory input. There is reduced 
inhibition in schizophrenia of the neuronal responses to redundant 
sensory input as first noted by Lawrence E. Adler et al. in acutely 
psychotic, unmedicated schizophrenia patients. Sensory gating is studied 
in the laboratory using scalp EEG.  
 Robert Freedman, Adler, and Sherry Leonard provided evidence 
for linkage of the P50 sensory gating phenotype to chromosome 15q14 in 
schizophrenia pedigrees. Subsequently,  an association of P50 deficit in 
schizophrenia with allelic variants in the promoter region of the α-7 
nicotinic cholinergic receptor subunit gene  on the 15q locus was 
described. .The drug probe studies also further support the  role of low-
affinity nicotinic receptors in the P50 gating abnormality in 
schizophrenia.  
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Prepulse Inhibition (PPI) 
 In the presence of a sudden, intense sensory input (e.g., loud 
sound), humans reflexively startle. The startle reflex consists of 
contractions of skeletal and facial muscles that is observed across species 
and meant to be a defensive response. The startle reflex is muted or 
inhibited in the presence of a preceding, weak sensory stimulus 
(prepulse). This muting of the startle response by prepulse is called 
prepulse inhibition and is observed when the prepulse occurs 30 to 500 
milliseconds before the pulse (i.e., the intense stimulus eliciting the startle 
reflex). The maximum inhibition occurs between 60 and 120 milliseconds 
of interstimulus interval. Investigators have argued that PPI is a brain 
mechanism by which the nervous system screens or gates out the milieu 
noise in order to process salient aspects of the environment. In this 
context, the more salient the prepulse, the stronger it inhibits the startle 
response to pulse. Schizophrenia patients generally show normal startle 
response; however, this patient group shows reduced inhibition of the 
startle response by the prepulse compared to healthy control subjects. 
 A defect in the neuronal nicotinic acetylcholine receptor 
expression-genotypic or phenotypic has been implicated in the 
neuropathophysiology of schizophrenia. Smokers without schizophrenia 
have increased nicotinic receptor binding in postmortem brain 
hippocampus, caudate and cortex  with increasing tobacco use.Whereas , 
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schizophrenic smokers have reduced nicotinic receptor levels  and this 
finding is  indicative of  an  abnormally regulated  high-affinity neuronal 
nicotinic receptors after  the initiation of nicotine use.  
       One important theory that links schizophrenia and tendency for 
nicotine addiction   is the presence of abnormalities in auditory sensory 
gating in patients with schizophrenia. Sensory gating is being mediated 
by functions of the  α-7 nicotinic cholinergic receptor 36. Nicotine in all its 
forms  (smoking and smokeless ) improves abnormal sensory gating in 
humans and animals. 
    The cognitive and neurophysiological  deficits postulated to be 
improved with nicotine include : (1) abnormalities in smooth pursuit eye 
movements (2) sensory gating (3) transient normalization of the P50 
inhibition abnormality( especially by high doses of  nicotine)  in  both 
schizophrenic patients  as well as   their relatives (4) working memory 
and selective attention performance and  (5) selective enhancement of  
visuospatial working memory  in smoking  schizophrenics. However,  a 
study by Harris et al., stated that  nicotine mainly affects  attentional 
deficits  without  as much effects  on other aspects of neurocognition like  
memory,learning ,  visuospatial  or constructional abilities. 37  
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SELF MEDICATION HYPOTHESIS IN SCHIZOPHRENIA 
 Smoking might be having a beneficial effect in schizophrenia by 
improving  atleast to a certain extent its symptoms and also by decreasing 
the antipsychotics induced   extrapyramidal side-effects  and this is the 
core concept of  ‘the self-medication hypothesis’ 38. 
     As discussed earlier the improved symptoms include cognitive 
functions like  focused attention, sustained attention and aspects of 
memory like  working memory, short-term memory and recognition 
memory. Studies using evoked potentials (P50 paradigm) and prepulse 
inhibition of the acoustic startle reflex suggest that deficient preattentive 
information processing, a core feature of schizophrenia illness, is 
improved following treatment with nicotine. Smoking can also improve 
extrapyramidal secondary effects of antipsychotic medication by virtue of 
its capacity to  induce cytochrome P4501A2, an enzyme system involved 
in the metabolism of several antipsychotics and by causing few biological 
changes in the neurotransmitter systems of the brain. 
ANTIPSYCHOTIC INDUCED MOVEMENT DISORDERS: 
 The incidence of  antipsychotic induced parkinsonism is lesser in 
nicotine dependant schizophrenic patients who smoke cigarettes or use 
other forms of tobacco and the  need for  use of prophylactic 
anticholinergic medication is  lower in neuroleptic - exposed patients with 
schizophrenia who smoke . The plausible explanation is thus that nicotine 
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enhances central dopaminergic activity and thus corrects the 
hypofunctioning of the  central dopaminergic hypofunction in 
nigrostriatal dopamine systems produced by dopamine antagonists and 
hence decreases the incidence of antipsychotic induced parkinsonism. 
      Further a  higher prevalence of Tardive Dyskinesia in smokers than 
non-smokers has been  found 39. The proposed mechanisms  include 
1)increased dopaminergic activity from nicotine40 leading to nigrostriatal 
hypersensitivity to dopamine 2) neurotoxicity from the free radicals in 
cigarette smoke leading on to a  damage to catecholaminergic neurons in 
the basal ganglia. 3) smoking induced increased risk of cerebrovascular 
pathology.41 
 SMOKING AND ANTIPSYCHOTICS 
 It has reported in studies that smoking is more frequent among  
young  male patients with schizophrenia,in those who have  an earlier 
onset of illness,and those who more often require inpatient management  
either by reason of the severity of symptoms or due to poor drug 
compliance and they often require  higher doses of antipsychotic 
medication  to achieve symptom remission.  
    Since cigarette smoke causes  metabolic induction, they  tend to 
consistently receive higher doses of antipsychotics42. By reason of its 
effects on antipsychotic medications , schizophrenic  smokers  display 
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lesser  negative symptoms and also lesser  parkinsonism than non-
smokers with schizophrenia. 
 BLOOD LEVELS OF ANTIPSYCHOTIC MEDICATIONS  
 Clinical improvement in schizophrenia is affected by cigarette 
smoking, by its lowering of blood antipsychotic medication levels.The 
hydrocarbon agents in smoking and  not nicotine per se  are known liver 
enzyme inducers ( effected through cytochrome  P450 1A2 isoform 
induction) and hence increase drug metabolism – those of neuroleptics , 
anti anxiety and anti depressants. There has been documentations in 
studies that blood levels of neuroleptics like fluphenazine & haloperidol  
are lowered  by upto 50% due to smoking. As per reports of some clinical 
epidemiological studies, smokers are prescribed higher neuroleptic doses 
than those who don’t smoke. 
 The effect of schizophrenia treatment with haloperidol and  
clozapine on smoking behaviour , as studied by Mc Evoy et  al43, is that 
haloperidol  treatment resulted in increased smoking  and  increase in 
blood levels of nicotine, when compared to the medication free baseline 
conditions. Further in a similar group of smokers with schizophrenia ,the 
smoked cigarette  numbers and  the expired air- carbon monoxide amount 
decreased following a clozapine treatment for 12 months , when 
compared to baseline  measures during haloperidol treatment. 
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 It is  interesting to note that treatment with clozapine improves P 
50 auditory evoked response gating. This fact suggests that , through this 
effect on sensory gating, clozapine treatment might be modulating the 
smoking behavior.Not only this, clozapine can also enhance the 
hippocampal acetyl choline levels.As a result of this  acetylcholine-
enhancing effect, patients on clozapine have near normal levels of P50 
suppression.Acetyl choline  levels are also increased by ondansetron, a 
5HT3 antagonist.Similar to   clozapine,P 50 sensory gating is enhanced in 
schizophrenic patients by ondansetron also. Donepezil, an Acetyl Choline  
esterase inhibitor,  enhanced P 50 sensory gating in such patients44. . 
MANAGEMENT OF SMOKING IN SCHIZOPHRENIA 
 Although smoking cessation may be more difficult for people with 
schizophrenia than for others 45, clinicians still should discuss the hazards 
of smoking and encourage patients to reduce their cigarette consumption. 
Some evidence suggests that group therapy combined with a nicotine 
patch may be effective in helping patients with schizophrenia reduce 
smoking46. 
 Cigarette smoking among these patients may be more than just a 
‘‘bad habit,’’ however47. One small study showed that haloperidol was 
associated with an increase in smoking and nicotine levels, whereas 
others suggest that switching treatment from typical antipsychotics to 
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clozapine may lead to a decrease in smoking . A controlled study 
suggested that atypical antipsychotic medications may facilitate smoking 
cessation more than typical agents.  
          Few studies have  reported that outpatients with schizophrenia 
often reported retrospectively a decrease in smoking(ie. decreased daily 
cigarette consumption) after  such patients are treated with the atypical 
antipsychotic  clozapine compared to their  smoking status  when they 
were treated with typical antipsychotics like haloperidol ,chlorpromazine 
etc. 48  
         Data also are emerging about the beneficial effects of bupropion 
combined with psychotherapy on nicotine addiction in this patient 
population . In the case of  severely addicted patients, the advisable 
medications include: combined nicotine  gum and patch therapy; 
bupropion  combined with either nicotine patch , nicotine inhaler or 
nicotine nasal spray 49 . 
 A recent  publication on the management of   acutely disturbed and 
agitated patients with schizophrenia advises that smoking status should be 
included in the assessment of agitation and nicotine replacement should 
be included in the treatment of those who are smokers which helps in 
bringing down the agitation in such patients 50. 
        The  Food and Drug Administration for tobacco-dependence 
treatment  approved five  different types of nicotine-replacement 
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therapies— viz . nicotine polacrilex (gum), the nicotine transdermal 
patch, nicotine inhaler, nicotine nasal spray, and the nicotine lozenge— 
all with nearly  similar efficacies and with a very low overall risk for 
abuse liability 51. Both the nicotine patch and bupropion have been found 
to be tolerated  well  and to improve outcomes in schizophrenia in small 
studies. 
      Pharmacologic and psychosocial interventions may be useful in 
assisting patients to reduce smoking and ultimately, it is hoped, smoking-
related disease and mortality. 
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AIM OF THE STUDY 
 
  To study the prevalence and severity of Nicotine dependance in 
Schizophrenic patients and to study the clinical correlates in relation to  
the severity of dependence like  Positive and Negative 
symptoms,antipsychotics induced abnormal involuntary movements  and 
to compare it among nicotine dependant and non-dependant patients. 
Objectives of the Study 
1. To study the prevalence and severity of Nicotine dependance in 
Schizophrenic patients and its association with the duration of 
illness, Duration of Untreated Psychosis(DUP) and to compare it 
among  the study(nicotine dependant) and control group(non –
nicotine dependant patients)            
2. To compare between the two groups ,the symptom correlation with 
the severity of nicotine dependance: 
a. Positive symptoms 
b. Negative symptoms 
3. To compare the  Chlorpromazine equivalents of various 
antipsychotics  used to treat Schizophrenic  patients with and 
without nicotine dependence .   
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4. To study about the incidence of antipsychotic induced abnormal  
involuntary movements –akathisia, drug induced parkinsonism and 
tardive dyskinesia  among the two groups. 
Study Design: 
A cross-sectional case-control study of 30 cases and 30 control male 
outpatients with Schizophrenia. 
 
Period of study: 
March 2011 to June 2012 
 
Subjects: 
ª Cases: Schizophrenic patients with history of smoking and /or using 
smokeless tobacco  
ª Controls: Schizophrenic patients without history of smoking 
 
Inclusion Criteria: 
1. Patients who fulfilled the ICD -10 Research Diagnostic Criteria for 
schizophrenia and with history of smoking or smokeless tobacco 
use.  
2. Male patients in the age group 15-50 years. 
3. Patients who consented for the study. 
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Exclusion Criteria: 
1. Past and current H/O of another Axis I disorder. 
2. Co-morbid substance use.  
3. Mentally retarded patients 
4. Demented patients. 
 
HYPOTHESIS  
1. In Patients with Schizophrenia  with nicotine dependence the 
duration of illness is longer than the control group(non nicotine-
dependant). 
2. Patients with Schizophrenia with nicotine dependance have a 
longer duration of untreated psychosis(DUP) . 
3. The severity of smoking is higher for smoking tobacco users than 
the users of smokeless tobacco. 
4. Patients with Schizophrenia with nicotine dependance  have 
significantly higher scores on the positive symptoms scale of 
Schizophrenia . 
5. Patients with Schizophrenia with nicotine dependance  have 
significantly lower scores on the negative symptoms scale of 
Schizophrenia. 
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6. Patients with Schizophrenia with nicotine dependance need higher 
doses of antipsychotics(Chlorpromazine equivalents) to treat their 
psychotic symptoms. 
7. Patients with Schizophrenia with nicotine dependance more often 
develop symptoms of drug induced Tardive dyskinesia. 
8. Patients with schizophrenia who smoke have lesser prevalence of 
drug induced extrapyramidal symptoms. 
9. Patients with schizophrenia who smoke have lesser prevalence of 
drug induced akathisia as  compared to those who do not smoke. 
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MATERIALS AND METHODS 
Setting: 
 This study was carried out  in the Out patient Section of the  
Department of Psychiatry, Tirunelveli Medical College Hospital.This 
hospital is the tertiary level referral centre for the urban and rural 
population of Tirunelveli.The study was approved by the Ethical 
Committee of Tirunelveli Medical college.A formal written consent in the 
mother tongue was obtained from all participants included in the 
study.All participating patients were given the information sheet 
pertaining to the nature of study. 
 
Tools used: 
1. Semi-Structured Proforma to collect Sociodemographic 
data,Family History, Disease type, age at onset of smoking,age at 
onset of illness,H/O recent treatment of medication induced 
movement disorders and its details,H/O abstinence,Reasons for 
smoking,duration of illness,age at start of treatment for the 
illness,treatment details including drug doses. 
2. Nicotine dependence was measured by  
a. Fagerstorm’s Test for Nicotine Dependence (FTND) for 
smoking tobacco-cigarettes and beedis. 
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b. The Fagerstörm’s Test for Nicotine Dependence-Smokeless 
Tobacco (FTND-ST) 
 
3. The symptoms were measured by  
a. Scale for Assessment of Positive Symptoms(SAPS)  
b. Scale for Assessment of Negative Symptoms(SANS) 
 
4. Abnormal Involuntary Movements were assessed using: 
a. Barney’s Akathisia Scale(BAS) 
b. Modified Simpson Angus Scale(MSAS) 
c. Abnormal Involuntary Movement Scale(AIMS) 
Statistical Analysis:  
  Central tendencies and the dispersion of the variables were studied 
using descriptive statistical methods such as mean, standard 
deviation.The study group (Nicotine dependent) and control group 
(Nicotine non users) were matched in respect of their demographic ,socio 
and economic status to identify the confounding of SED (Socio Economic 
and Demographic) variables. The matching was performed according to 
the type of variables by either Parametric or Non- parametric test such as 
Students ‘t’ or χ2 test. The prevalence of Nicotine dependence was 
identified by comparing the two groups in respect of their Schizophrenia 
characteristics by respective test of significance. The relationship 
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between the Nicotine dependence with smokers in respect SAPS and 
SANS was studied by Spearmans’ rank correlation test among the 
Nicotine dependence subjects. The above statistical procedures were 
performed by the statistical package IBM SPSS statistics 20. The P - 
values less than 0.05 (P<0.05) were treated as significant in two tail 
condition. 
Fagerstorms Test for Nicotine Dependance(FTND) 52 
 The FTND is a short scale comprising of  6 items which quantify  
nicotine dependance. The smoking rate and the time lag between waking 
and the first cigarette is being  scored 0 to 3.If the patient smokes fewer 
cigarette per day and if he takes a longer time for his first cigarette of the 
day he gets a lower score.The other 4 variables which are rated in a 
dichotomous manner include are smoking even while he is ill, having 
difficulty in  refraining from smoking in places where it is forbidden , 
smoking cigarettes more heavily especially in the mornings and having 
difficulty in giving  up the day’s first cigarette.These variables  are scored 
as yes (1) or no (0). The overall  scores for severity of dependance  : 0–2 
:very low dependance , 3–4: low dependance , 5 :moderate dependance, 
6–7 :high dependance, 8–10: very high dependance. 
The Fagerstorm Test for Nicotine Dependence-Smokeless Tobacco 
(FTND-ST)53 is similar to the FTND scale  and this scale measures the 
severity of using smokeless tobacco by estimating the number of 
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pouches/tins or cans used instead of the number of cigarettes smoked..It 
is scored in the same manner as FTND. 
 SAPS (Scale for the Assessment of positive Symptoms) and 
SANS (Scale for the Assessment of negative symptoms) These scales 
were sourced from the University of Iowa press, 1983.These scales were 
developed by Nancy Andreasen. These scales are used for the assessment 
of positive and negative symptoms, principally those occurring in 
schizophrenia. Both the instruments are used in a way complimentary to 
each other. They have been widely used in many studies and well tested 
for reliability and validity. The SAPS contains 35 items divided into 5 
domains i.e. Hallucinations, Delusions, Bizarre behavior, Positive formal 
thought disorder and inappropriate affect. The SANS contains 24 items 
divided into 5 domains i.e. Affective flattening or blunting, Alogia, 
Avolition-apathy, Anhedonia-asociality and Attention. Items in both the 
scales are scored between 0 (none) and 5 (severe). 
Barney’s Akathisia Scale54 
 Using this scale patient is  examined while they are sitting, 
standing, while talking about a neutral topic for a minimum of two 
minutes in each position. The subjective symptoms should also be elicited 
by direct interrogation.The  scores are  based on the Objective Akathisia, 
Subjective Awareness of Restlessness and Distress. The scores are given 
on a  4 point scale from 0 – 3 .Total score ranges from 0 to 9. 
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Modified Simpson Angus Scale55 
 
 It is a 10-item rating scale to assess for the presence of  neuroleptic 
induced parkinsonism.One item measures gait hypokinesia, 6 items 
measure rigidity at the various body regions  and 3  items measure 
glabella tap, tremor and salivation. Each item is rated on a 5-point scale 
of severity : 0 = normal to 4 = most severe. This scale has  good internal 
consistency ,reliability . Inter-rater reliability  was also good. 
 
Abnormal Involuntary Movement Scale56 
 
 This scale  has 12 items, each  rated on a five-point severity scale 
ranging from 0 to 4. Ten items assess the  abnormal movements in 
different  body regions like orofacial area, extremities, and trunk,  the 
global severity; two items rate the  dental conditions which  can make the 
diagnosis of dyskinesia difficult.It is a highly reliable and valid tool. 
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RESULTS & OBSERVATIONS 
                                                   Table-1 
 Table showing the comparison of Age distribution and 
Educational Status of Study and Control groups . 
S.No. Variable Cases(N=30) 
 
Controls(N=30) 
 
Statistics 
n % n % 
1. Age group(years)      
 
t value= 
0.289 
 20-24 1 3.4 1 3.4 
 25-29 7 23.3 7 23.3 
 30-34 6 20.0 5 16.6 
 35-39 7 23.3 7 23.3 
 40-44 6 20.0 8 26.7 
 45-49 3 10.0 2 6.6 
      Mean ± S.D. 34.9±6.8 35.4±6.5years  
2. Education    
 Uneducated 4 4  
  χ2   =3.393 
   df=4          
 Primary 9 7 
 High School 13 13 
 Hr. Sec 4 3 
 Graduate             0             3 
*p<0.05 
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 The study and control groups were compared in the above table -1. 
The mean ages ±Standard Deviation of the study group and control group 
were 34.9±6.8 and 35.4±6.5years respectively. The t value was 0.289 and 
the difference was statistically not significant (p>0.05). 
 In the above table-1, the education was matched and there was no 
significant  difference  between the two groups (p>0.05).  
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Table -2 
 Table showing comparison of the  sociodemographic status 
among the study and control group. 
S.N
o 
Variable No of persons 
 
Statistical Test 
Cases 
(N=30) 
Controls 
(N=30) 
 
 
1. 
 
Occupation 
n n χ2 Significan
ce   
 Employed 7 9 0.341 
df=1 
p>0.05 
  Unemployed 23 21 
2. Social class   
 Low 28 28 0.0 
 
df=1 
p=1 
 Middle 2 2 
3. Family 
history 
    
 Yes 12 10 1.153 
df=1 
p>0.05 
 No 18 20 
4. Type of 
Family 
    
 Nuclear 15 15 0.0 
df=1 
p=1.00 
 Joint 15 15 
5. Marital 
status 
    
 Married 11 15 1.343 
df=3 
p>0.05 
 Un married 13 9 
 Single 4 4 
 Divorced 2 2 
49 
 
 
 The two groups were matched in respect of their occupation 
(p>0.05), social class (p=1.00), family history (p>0.05), family type 
(p=1.00),the marital status(p>0.05).  
 The study (Nicotine dependant) and control (non Nicotine 
dependant) groups were matched in respect of their age, education, 
occupation, social class, family history, type of family and marital status. 
The results revealed that they were not significantly different and hence 
they were comparable. 
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  Table 3 
 Table showing the comparison of the Duration of illness between 
study and control groups: 
S.No. No. of  years Study Group 
(N=30) 
Control Group  
 (N=30)  
 t value 
n      % n            % 
1. 0-10 6 20 10 33.3 0.671 
2. 11-20 15 50 18 60 
3 21-30 9 30 2 7.3 
 Mean± S.D. 13.5±7.9 12.3±5.8 
*p<0.05 
 The  duration of  illness was compared between the study and 
control groups . Thus the mean duration of illness among nicotine 
dependant study group was  13.5±7.9 and the mean among the non 
nicotine dependant control group was 12.3±5.8. The difference between 
the duration of illness in the two groups  was not significant. 
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Table 4 
 Table showing the comparison of Duration of Untreated 
Psychosis(DUP) between the study and control group:  
Months Study 
group(N=30) 
Percentage Control Group 
(N=30) 
Percentage 
 N % N % 
≤5 0 0 3 10 
6-11 3 10 9 30 
12-17 7 23.3 4 13.3 
18-24 9 30 14 46.6 
≥ 25 11 36.6 0 0 
 Among the nicotine dependant group, about 67% of the patients 
presented after 18 months of onset of their illness and none of them 
presented within 6 months of onset of illness.Whereas in the control 
group only 47% presented after 18 months of onset of illness. 
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Table 5 
Table comparing the Duration of Untreated Psychosis(DUP) between 
the study and control group 
No. of 
years 
Study Group (N=30) 
 
Control Group(N=30)  
 
Statistical 
test 
 n         % n        %  
<1 3 10 12 40 χ2  = 
5.688 
df=2 
1-2 16 53 18 60 
>2 11 37 0 0 
p<0.05 
 The duration of untreated psychosis between the study and control 
group was compared in the above table 5 and the difference was found to 
be statistically significant.p<0.05.Thus the duration of untreated 
psychosis was significantly longer in the nicotine dependant group. 
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Table:6 
Table showing Severity of nicotine dependance among smoking and 
smokeless tobacco users 
FTND& 
FTND-
ST 
Score 
Degree of 
dependance 
Nicotine 
dependant 
(smoking) 
group(N=30)
Percentage
% 
Nicotine 
dependant 
(smokeless)group 
(N=30) 
Percentage
% 
     0-2 very low 5 16.6 19 63.3 
     3-4 Low 4 13.3 5 16.6 
      5 Medium 1 3.3 0 0 
     6-7 High 6 20 2 6.6 
   8-10 very high 14 46.6 4 13.3 
 
 It was found from the above table that about 66.6 % of the nicotine 
dependant group of the smoking type had high to very high dependence 
for nicotine.Whereas in the users of smokeless tobacco about 63.3% had 
very low dependence for nicotine. 
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                                    Duration of untreated Psychosis 
 
Frequen
cy 
 
 
 
Months 
 
Severity of nicotine dependance 
 
Frequency 
                                                      Fagerstorm s scores 
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Table-7 
 Table showing the   Prevalence of Nicotine dependence among 
users of  smoking tobacco and  smokeless tobacco. 
Category 
 
Number  of persons(N=30) χ2  
Nicotine 
dependance 
Non nicotine 
dependance 
 
n n 
Smoking tobacco 26 4 9.075**
df=1 Smokeless 
tobacco 
14 16 
  ** p<0.001 
 The Prevalence of Nicotine dependence among users of  smoking 
tobacco and  smokeless tobacco is shown in the above table-7. The 
nicotine dependence among the two types of tobacco use was compared 
and the χ2 was 9.075 with a significance of p<0.001.This showed that 
more patients using smoking tobacco were dependant on it as compared 
to the dependance in smokeless tobacco users.  
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Clinical Correlates of Nicotine dependence in Schizophrenia: 
The two groups were compared in respect of their Duration of Untreated 
Psychosis(DUP), Positive symptoms (SAPS mean score), Negative 
symptoms (SANS mean score) and Chlorpromazine(CPZ) equivalents in 
table 8. 
                                                     Table-8  
 Table showing the comparison of Clinical correlates between Study and 
Control groups. 
S.N
O 
Clinical Correlates Cases (N=30) Control 
(N=30) 
Differen
ce b/w 
means 
‘t’ 
Mean SD Mean SD 
1 Duration of 
untreated 
Psychosis 
(months) 
20.9 8.5 15.1 8.3 5.8 2.684*
2 SAPS 11.3 4.6 5.5 2.7 5.8 6.004**
3 SANS 13.1 4.6 9.8 3.8 3.3 3.102* 
4 CPZ equivalents 783.3 343.5 428.3 226.9 355.0 4.723**
df=58   p<0.001**         p<0.05* 
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              The above table 8 compares the clinical correlates between the 
groups. The mean durations of untreated Psychosis of study and control 
groups were 20.9±8.5 and 15.1±8.3 respectively and the difference 
between means was statistically significant (p<0.05).The mean SAPS 
score were 11.3±4.6 and 5.5± 2.7 respectively and difference between 
means was statistically  highly significant (p<0.001). Similarly the means 
of SANS score between the two groups were 13.1± 4.6 and 9.8±3.8 
respectively and the difference was also statistically significant (p<0.05). 
The means CPZ equivalents of study and control groups were 
783.3±343.5 and 428.3±226.9 respectively and the difference between the 
two groups was statistically highly significant (p<0.001).  
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Relationship between Nicotine dependence with Positive (SAPS) and 
Negative (SANS) symptoms: 
                                                     Table -9 
Table showing the Correlation between Nicotine dependence with SAPS 
and SANS scores. 
Variable Rank Correlation “r” r2 % of r2 
Positive symptoms 0.415 0.172 17.2* 
Negative symptoms 0.013 0.000169 0.0169 
*p<0.05         
The above table -11 shows the correlation of positive and negative 
symptoms scores of study group with the severity of nicotine dependence. 
The results revealed that nicotine dependence was significantly and 
positively correlated with their positive symptoms.Hence 17.2% positive 
symptoms were depending upon the nicotine dependence. The Nicotine 
dependence was not significantly correlated with their negative symptoms 
(p>0.05) 
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Table -10 
 Table showing the  comparison of  abnormal involuntary 
movement-Tardive Dyskinesia between two groups.(AIMS scale scores) 
AIMS 
scores 
Number of persons χ2  
Study 
Group  
N=30 
Control 
Group  
N=30 
Total 
Positive 7 1 8 5.192* 
df=1 Negative 23 29 52 
*p<0.05 
 The study group and control group were compared in respect of 
their abnormal involuntary movement scales for Tardive dyskinesia in 
table-10. The Positive Score abnormal  involuntary movement was 
significantly associated with Nicotine dependent group (p<0.05). 
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Table 11 
 Table comparing the scores of  abnormal involuntary movement-
drug induced extrapyramidal symptoms( Modified Simpson Angus Scale 
scores) of the two groups:   
MSAS Score Study Group  
N=30 
Control Group  
N=30 
Statistical test 
<3 5 11 χ2  =2.131 
df=1 
>3 25 19 
*p<0.05 
 The two groups were compared in respect of their Modified 
Simpson Angus Scale scores for drug induced parkinsonism in table-11.A 
score <3was a normal score(absence of drug induced extrapyramidal 
symptoms) and a score of >3 was indicating the presence of drug induced 
extrapyramidal symptoms. The score was not  significantly different 
among the study and control group (p>0.05) 
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                                               Table -12 
Table showing the comparison of Akathisia (Barne’s Akathisia scale 
scores)between two groups. 
BAS Scores Number of persons χ2   
Study 
Group  
N=30 
Control 
Group  
N=30 
Total 
No akathia 23 19 42 1.758 
df=2 Questionable 5 6 11 
Mild 2 5 7 
*p<0.05 
 The drug induced extrapyramidal symptoms-Akathisia between the 
study group and the control  were compared and shown in the above 
table-12. The results revealed that there was no significant difference  in 
the Barne’s Akathisia scores  between the two groups (p>0.05). 
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DISCUSSION 
 This study was conducted in the outpatient department of the 
Department of Psychiatry,Tirunelveli Medical College Hospital.Ethical 
committee approval for conducting the study was obtained from the 
Institutional Ethical committee in February 2011(annexure).The study 
was carried out in the period between March 2011 and September  2012.  
 The cases and controls were selected based on the selection criteria 
and the sample was selected by stratified random sampling.An 
information sheet(annexure) regarding the illness, the smoking patterns 
and the purpose of the study was provided to the patient.Informed consent 
was obtained in the mother tongue. For illiterate patients the contents 
were read out and then written consent was obtained(annexure).Only 
those patients who consented to participate in the study and were co-
operative for interview were recruited. 
      The study and control subjects were matched in respect of their age, 
education, occupation, social status, family history, type of family and 
marital status and found that they were not significantly different 
(p>0.05). And hence the two groups were not confounded with the above 
attributes. They were comparable study subjects. 
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Prevalence of smoking and duration of illness: 
 The  duration of  illness was compared between the study and 
control groups .The mean duration of illness among nicotine dependant 
study group was  13.5±7.9 and the mean among the non nicotine 
dependant control group was 12.3±5.8. The mean of the duration of 
illness among smokers was higher than the control group. The difference 
between the two means was not significant. Among  the study group 
30%(n=9) had the longest duration of illness(21-30)years as against 
13%(n=2) in the control group.Thus patients with very long duration of 
illness tend to be nicotine dependant.This implies that all patients with a 
longer duration of illness should be screened for nicotine dependence and 
suitable deaddiction choices be offered. 
Prevalence of nicotine dependence among different types of tobacco 
users: 
 The dependence rates for the various types of tobacco used by our 
study group for cigarettes and beedis was 54%, for chewing /smokeless 
tobacco in the form of ganesh tobacco,shanthi tobacco ,paan masala it 
was13%.Patients with very low to low dependence  usually chewed 
tobacco and spit it out after about an hour or so while the highly 
dependant group both chewed and swallowed it.Patients who used both 
accounted for 33% of the dependant group.This is closer  to the values 
quoted in a study among psychiatric population by Praba Chandra et 
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al(2005) ,NIMHANS which stated that smoking  Beedis - 56% was more 
than the use of cigarettes -30%.According to their study the commonest 
type of tobacco used was Chewing tobacco -67%  and Cigarettes or 
beedis (with chewing) -45% while in our study population it was 
13%(pure chewing tobacco) and both smoking and chewing type 
33%.Hence we infer that the prevalence of chewing tobacco as a 
substance of dependence is much lower when compared to that reported 
by other Indian studies done on a heterogenous population including both 
north and south Indian patients.In a study by Srinivasan and Thara in 
2002,the prevalence of smoking among male schizophrenic patients using 
both Cigarettes or beedis (with chewing) was 31.6%  which is much 
closer to our results of 33%. 
 In the study group  patients ,among the smokers,13%(n=4) were 
non-dependant on cigarette or beedis and among the smokeless tobacco 
users 52%(n=16)were non dependant on chewing type of tobacco.The 
difference of nicotine dependance among the two groups(smoking and 
smokeless tobacco users) was statistically significant (p<0.001) .The 
prevalence of nicotine dependance among both smoking and smokeless 
forms of tobacco is 66%.This is twice that of the prevalence of the 
general population as quoted in a study by Subramanian et al in  (2004). 
Rates of nicotine use in schizophrenic patients have been reported to 
range from 58% to 90% according to Hughes et al(1986). 
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Smoking prior to onset of Schizophrenia: 
 Further 83% of the patients started smoking prior to the onset of 
schizophrenia.This is slightly lesser than  the value noted in a study by 
Ciara Kelly & Robin McCreadie(2000) which stated that almost 90% of 
patients had begun to smoke before schizophrenic illness onset . Further it 
is more than that noted by Zhang XY et al(2012) in their study among 
Chinese population which showed that 73% smoked prior to their illness 
onset. 
Number of years smoked prior to onset of schizophrenia: 
 Regarding the average number of years smoked prior to the onset 
of schizophrenia,among nicotine dependant patients in our study 
population it was found to be 7.5 years with a standard deviation of 
5.86.This appears to be very close to that noted by  Zhang XY et al(2012) 
in their study among Chinese population which showed that the majority 
of patients in their study smoked 7.6 years prior to the onset of their 
illness . 
Age at onset of Illness: 
 In the nicotine dependant group, the average age at which 
schizophrenic illness had started was  22.1±4.9 years  while it was 
20.4±2.7 years  in the non nicotine dependant  group.This difference 
might be accounted for as an indirect evidence of the self medication 
hypothesis which states that schizophrenics may smoke to alleviate 
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atleast partially some of their troubling psychotic symptoms. Since many 
of the smoking  patients  begin their habit  before the  onset of the illness, 
a  common vulnerability to both the disease and the dependance has been 
proposed. The reduction of  positive symptoms by long term nicotine use 
is probably by a  potential correction of the dissociated  cortical–
subcortical  dopamine activity that occurs in  schizophrenia . However in 
the severe cases of schizophrenia ,‘self-medication’, even with greater 
amounts of nicotine has not been found to  be effective. 
Duration of Untreated Psychosis(DUP) 
 Among the nicotine dependant group,about 67% of the patients 
presented to treatment  after 18 months of onset of their illness.Whereas 
in the control group only 47% presented after 18 months of onset of 
illness. 
        The duration of untreated psychosis in the study group was  >2 
years in 37% among the nicotine dependant patients while none of the 
patients in the control group had DUP of >2years.The difference of DUP 
between the two groups was statistically significant.(p<0.05)  
 Although there are numerous confounding factors having a role to 
play in influencing DUP other than smoking viz 
• Gender:: males have a long duration of untreated psychosis than 
females 
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• age at onset of illness: longer DUP was significantly related to 
younger age at onset of illness57 
• baseline symptoms: longer DUP to be associated with higher levels 
of at least some aspects of negative or deficit symptoms at 
presentation  
• premorbid adjustment:lower premorbid adjustment to be 
significantly associated with longer duration of untreated 
psychosis . 
•  treatment response :Shorter duration of untreated psychosis 
generally predicts  a better response to antipsychotic treatment. 
      Since our study group and control group were matched based on 
socio-demographic variables and it was a homogenous group of male 
schizophrenics,the difference in DUP between the two groups may be 
linked to nicotine dependence. 
Reasons attributed: 
 The most common reasons attributed by smokers for smoking 
included the need  to reduce the hearing of voices and to reduce 
suspiciousness :37%, to decrease confusion &distress :17%, to feel 
energetic &to reduce dullness : 13%, to reduce irritability :10%, habit, to 
relax :7% 
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      Thus there is some data to support the self medication hypothesis that 
smoking improves positive and negative symtoms of schizophrenia from 
the reasons given by the smokers. 
SEVERITY OF NICOTINE DEPENDANCE 
 The severity of dependence: 
  to smoked tobacco:47% -severe 
  to smokeless tobacco:13%-severe  
 We find   that about 66.6 % of the nicotine dependant group of the 
smoking type had high to very high dependence for nicotine.Whereas in 
the users of smokeless tobacco about 63.3% had very low dependence for 
nicotine.Past studies indicated that 68% of  schizophrenic smokers were 
found to be  heavy smokers who smoked in an average more than 25  
cigarettes daily compared with only 11% of the general population who 
smoke.Thus we see that the severity of nicotine dependence though being 
twice of  that in the general population,is still lower than the rates of 
severity which is quoted in the western population studies. In one of the 
Indian  studies  on tobacco use in male schizophrenic  patients, the 
prevalence of smoking was about  38% .In the study by Praba et al at 
NIMHANS(2005) it was found that 63% of the entire study population 
which included smokers with different psychiatric diagnosis  had 
moderate to severe nicotine dependence. 
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     From our study we see that the rate of  tobacco use  among Indian  
psychiatric patients is lesser than that  reported in the western population . 
While in the west almost  one-half to two-thirds of all psychiatric patients 
smoke it is not so in our population.It is actually  difficult to interpret 
these cross-cultural variations, because they probably reflect the 
numerous confounding variables such as culture, income , population 
distribution  and availability and cost of tobacco products. For instance, , 
in India unlike that in the west there is a strong family system, even for 
the psychiatrically  ill individuals. Family members who take care of the 
patients  impose genuine restriction on smoking which results in lower 
rates of using tobacco in its various forms among the Indian 
schizophrenia  patients. The meagre income for patients in our population 
if at all they are employed  may also limit their affordability  to buy 
commercially-prepared tobacco products. 
 However there have also been few studies that  show that the rates 
of smoking appear to be high in affective disorders(Praba Chandra et al). 
Another  study  states that rates of smoking were higher  in subjects with 
schizophrenia  as  with other psychotic disorders. Further the severity of 
smoking  covaried with depression over time 58. 
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Clinical Correlates: 
SAPS  and SANS scores: 
 The duration of Psychosis among the Nicotine dependence 
Schizophrenia was significantly greater than (20.9±8.5 >15.1±8.3 
months) non Nicotine dependence Schizophrenia. The SAPS of the 
Nicotine dependence Schizophrenia was significantly greater than 
(11.3±4.6 > 5.5± 2.7) non Nicotine dependence Schizophrenia. The 
SANS of the Nicotine dependence Schizophrenia was significantly 
greater than (13.1±4.6 > 9.8±3.8) non Nicotine dependence 
Schizophrenia.These findings are closely similar to the  earlier studies 
which stated that smokers have more severe symptoms with higher scores 
on the Brief Psychiatric Rating Scale. 
Chlorpromazine Equivalents: 
 The Chlorpromazine Equivalents of the antipsychotics used in 
Nicotine dependence Schizophrenia was significantly greater than 
(783.3±343.5 > 428.3±226.9) non Nicotine dependence Schizophrenia. 
Individuals with schizophrenia who smoke are found to   receive  higher 
doses of antipsychotics than non-smokers . Thus the cytochrome p450  
inducing  effect of nicotine upon  antipsychotic metabolism  is 
inadvertently corrected by psychiatrists. Longitudinal studies comparing 
atypical antipsychotics with typical antipsychotics showed that the latter  
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are associated with increased smoking in some individuals , with a greater 
difficulty for quitting smoking too.George et al.(2000)  reported that  
many schizophrenic patients  reported a decrease in daily cigarette 
consumption after treatment having been treated with clozapine compared 
to their use when they were treated earlier with typical antipsychotics. 
Meszaros ZS et al (2011) 59 in their study findings have stated that  in 
patients with schizophrenia both conventional antipsychotic drugs and 
severe, treatment resistant schizophrenia  is associated with heavy 
smoking . 
Symptom  correlation with Nicotine dependence: 
 The symptoms of Positive (r=0.415) and Negative (r=0.456) were 
significantly (p<0.01) positively correlated with Nicotine dependence of 
Smokers. The Nicotine dependence of smokers determined the positive 
symptoms 17.2% (% r2) and negative symptoms were neither lower nor 
higher. Hence although the SANS mean score in the two groups differed 
in a statistically significant manner, there was no  correlation with the 
severity of nicotine dependence. 
           Our study does not support the findings by Patkar et al(2002) 
which showed that there was significant positive correlations  found 
between Fagerstrom scores and the total negative symptom scores.They 
further observed that smoking was not significantly associated with 
72 
 
positive symptoms.60The study by Zhang XY et al (2012)showed that 
smokers with schizophrenia tend to display lesser negative symptoms 
scores than non-smokers with schizophrenia 61 .  Thus the  possible 
beneficial effect of nicotine  on  the schizophrenic symptoms  and  on the 
antipsychotic induced movement disorders gets  obscured by the  higher 
incidence of severe nicotine dependance in the more severe forms of 
schizophrenia. 
Drug induced Abnormal Involuntary movements: 
Tardive dyskinesia:The Positive score of Abnormal involuntary 
movement scale  was significantly different between the study and 
control group.(p<0.05).Our results are similar to that by  Yassa et al. who  
reported that the prevalence of tardive dyskinesia was higher  among 
smokers than that  among nonsmokers with schizophrenia who are under 
treatment with  neuroleptic medication. There has also been a study 
contradictory to this by  Goff et al. which  reported that the propensity to 
develop  tardive dyskinesia was lower as measured by the  lower 
Abnormal Involuntary Movement Scale score  among smokers  in 
comparison with non smokers. 
Drug Induced Parkinsonism: The two groups were compared in respect 
of their Modified Simpson Angus Scale scores for drug induced 
parkinsonism in table-11. The score was not  significantly different 
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among those  with Nicotine dependence or the  nicotine non-dependant  
group (p>0.05). This result refutes the earlier studies which states that  
parkinsonism caused by prolonged antipsychotic use is lesser  in patients 
who smoke cigarettes, and that the use of prophylactic anti cholinergic 
medicines to prevent such drug induced parkinsonism is significantly 
lower in neuroleptic- exposed schizophrenia patients  who smoke 
.However comparison of the  dose and duration of  anticholinergic use 
was not an objective in our study. 
Akathisia:The results revealed that there was no significant difference  
between two groups  in terms of the Barne’s akathisia scores 
(p>0.05).There was a speculation by Wirshing et al who states that not 
only does  long-term smoking exposure cause  dyskinesia, but even  acute 
exposure to nicotine may  actually increase dyskinetic movements in 
prone individuals .However our study have no evidence to support 
this.This could be probably because most of our patient were chronic 
patients who might have been earlier been treated for akathisia and their 
symptoms might have abated. 
 Thus from the detailed analysis of our findings we come to 
understand that nicotine dependant  schizophrenics had a longer duration 
of illness and a longer duration of untreated psychosis.A huge majority of 
the nicotine dependant patients had started smoking before the onset of 
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illness and the age of onset of schizophrenia was later than the non 
dependant patients.We found that most of the nicotine dependent patients 
used smoking forms of tobacco and the severity of dependance was also 
higher among them when compared to smokeless tobacco users. Both the  
positive and negative symptoms were higher in the nicotine dependant  
schizophrenics ,the positive symptoms correlated positively with the 
severity of smoking while the negative symptoms did not correlate with 
the severity of nicotine dependance.The nicotine dependant  
schizophrenics  further needed higher chlorpromazine equivalent doses 
and also had higher prevalence of tardive dyskinesia.However the 
nicotine dependant  schizophrenics had extrapyramidal symptoms as 
equally as the non dependant patients.   
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LIMITATIONS OF OUR STUDY 
 There are few limitations in our study 
1. One limitation which  though ethically appropriate was the  
exclusion of patients who had  severe psychiatric instability in the 
form of  severe symptomatology, violent or assaultive behaviour,  
uncooperativeness  due to suspiciousness or gross disorganization 
etc . Such patients would have been even more vulnerable to 
tobacco use in its many froms, and having omitted such patients 
from our study population  may mean that the prevalence rates 
reported herein  actually  underestimates  the prevalence and 
severity  of tobacco use and dependence. 
2. The absence of another control group from the  general population  
in our study which  if we had included  would  have helped us 
analyse the difference in prevalence in the psychiatrically ill 
patients and  the normal population at large. 
3. Exclusion of other substance abuse grossly limited the number of 
patients who would have been severely dependant on nicotine. 
4. This being a cross sectional missed out the effects of the substance 
use on various stages of illness and with varying types of drugs 
prescribed in different periods. 
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5. Since females were not included in the study we are unable to 
generalize our findings to the whole psychiatric population. 
Exploring substance use among the female population would have 
given the gender comparisons and also helped understand the trend 
of substance use among female patients.  
6. Since we could not determine drug levels by laboratory methods 
the actual drug level measured as chlorpromazine equivalents 
could not be confirmed objectively.This is especially important 
because most of the psychiatric patients do not strictly adhere to 
the dosing regimens and have poor drug compliance. 
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CONCLUSION 
    The oft quoted assertion that smoking is the most commonly 
encountered preventable  cause of premature morbidity and mortality in 
the world raises important questions for the psychiatrist who is the most 
sought physician for the treatment  of substance dependant patients.Apart 
from the physical risks associated with smoking,it has been implicated in 
the increased mortality in schizophrenia.The association between 
smoking and schizophrenia is a long drawn debate whether one leads to 
another or if both have common neurobiological underpinnings. 
 In the recent years the need to   increase the  attention focused on  
improving the  care of  patients  with co-occurring mental illness and 
cigarette smoking or other  substance use disorders has been thoroughly  
felt even in the developing country like India. This physically  
underserved population require  the use  of evidence-based approaches to 
improve both the symptoms due to mental illness as well as to enable a 
smooth abstinence from drugs of abuse . This type of dual diagnosis is 
important because, smoking modifies psychiatric symptoms,  alters  the  
blood level of prescribed drugs  and  further serves as a clue for the 
presence of dependance for  other substance  of abuse. 
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The findings from our study include: 
1. In Patients with Schizophrenia  with nicotine dependence the 
duration of illness is longer than the control group but the 
difference was not statistically significant . 
2. Patients with Schizophrenia with nicotine dependance have a 
significantly longer duration of untreated psychosis(DUP) . 
3. The severity of smoking is significantly  higher for smoking 
tobacco users than the users of smokeless tobacco. 
4. Patients with Schizophrenia with nicotine dependance  have 
significantly higher scores on the positive symptoms scale of 
Schizophrenia . 
5. Patients with Schizophrenia with nicotine dependance  have 
significantly higher scores on the negative symptoms scale of 
Schizophrenia. 
6. Patients with Schizophrenia with nicotine dependance need higher 
doses of antipsychotics(Chlorpromazine equivalents) to treat their 
psychotic symptoms. 
7. The prevalence of drug induced Tardive dyskinesia in patients with 
Schizophrenia with nicotine dependance  is  significantly higher as 
compared to the control group. 
8. The prevalence of drug induced extrapyramidal symptoms did not 
differ significantly between the two groups. 
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9. The prevalence of drug induced akathisia did not differ 
significantly between the two groups. 
       Our study demonstrates that there is a definite association with the 
severity of nicotine dependence and the disease state.Also it shows that 
most of the  smokers  needed  higher doses of antipsychotic medication to 
ameliorate their symptoms. A few of them are more prone to develop 
abnormal involuntary movements due to their smoking.This study 
demonstrates that smoking be accorded a top priority in the treatment of 
people with schizophrenia since the lives of these patients are 
considerably deranged with tobacco use by increase of both morbidity 
and mortality .However, our study having been done on  stable out-
patients with schizophrenia ,may in future help the treating psychiatrist to 
select which individuals are more likely to improve their schizophrenic 
symptoms and their  extrapyramidal side effects using the upcoming  
nicotine patches or other nicotine agonists which are under clinical trials 
for treatment of cognitive dysfunctions in schizophrenia.  
  A significant  proportion of the schizophrenic smoker’s  meagre 
income  is spent on cigarettes especially in rehabilitation setups. It 
has been estimated that most schizophrenics who smoke afford to  
spend more than a third  of their monthly disability income on 
cigarettes .It is a common sight in most residential  institutions for 
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mentally ill patients that patients do work inorder  to earn for their 
cigarettes.Hence other ways of contingencies may be entertained.  
 The huge problem after treatment of schizophrenic patients is 
reintegration into the community. Smoking  will definitely have an 
influence on the  community integration because they will have  
lesser  income to spend on their  everyday needs  like clothing 
,housing etc.  
 Stigma for both smoking and schizophrenia can reduce  chances 
for success in obtaining a new employment ,in  housing and may 
limit the scopes for renewed peaceful  interpersonal relationships 
which have been put to strain due to the burden of illness and 
institutionalisation. 
 Patients with schizophrenia have the real need  to be offered 
treatment for one of the most common substance of dependence  namely 
nicotine  and it is our duty to protect their physical health.This study 
under scores the need to plan smoking cessation regimens for patients 
with Schizophrenia which might offer better control of clinical 
symptoms at the same time prevent the morbidity associated with 
heavy smoking among the recovering patients and aid a better 
psychosocial rehabilitation. 
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Appendix II – Semi Structured proforma 
Prevalence and Clinical correlates of  Nicotine Dependence in Schizophrenia 
Investigation Questionnaire 
Principal Investigator:  Dr. M. Amali Victoria, PG-MD Psychiatry, Tirunelveli Medical College. 
 
 
Appendix III SAPS 
 
 
Appendix  IV SANS 
 
 
Appendix  V Fagerstorm’s Test for Nicotine Dependence (FTND) for smoking tobacco-
cigarettes and beedis. 
 
 
Appendix  VI Fagerstörm’s Test for Nicotine Dependence-Smokeless Tobacco (FTND-
ST) 
 
 
 
Appendix  VII Barneys Akathisia Scale 
(BAS)  
 
Appendix VIII Modified Simpson Angus Scale(MSAS)            
 
 
 
 
Appendix  XI Abnormal Involuntary movement Scale(AIMS) 
 
 
 
Appendix X Disease information form 
ஆராய்ச்சித் தகவல் தாள் 
 
         திᾞெநல்ேவᾢ அரசுப் ெபாᾐ மᾞத்ᾐவமைனக்கு வᾞம் மனச்சிைதᾫ 
ேநாயாளிகளிடம்  நிலᾫம்  ᾗைகப் பழக்கத்ைதப் (Nicotine dependence) பற்றிய 
ஆராய்ச்சி இங்கு நைடெபற்ᾠ வᾞகிறᾐ. 
 
        மனச்சிைதᾫ ேநாயாளிகளிடம்  நிலᾫம்  ᾗைகப் பழக்கத்ைதப் பற்றி ஆய்வேத இந்த 
ஆராய்ச்சியின் ேநாக்கமாகும். 
 
         நீங்கᾦம் இந்த ஆராய்ச்சியில் பங்ேகற்க நாங்கள் விᾞம்ᾗகிேறாம்.இந்த 
ஆராய்ச்சியில் பங்ேகற்பதால் தங்களᾐ 
ேநாயின் ஆய்வறிக்ைகேயா அல்லᾐ சிகிச்ைசேயா பாதிப்ᾗக்கு  
உள்ளாகாᾐ என்பைதᾜம் ெதாிவித்ᾐக் ெகாள்கிேறாம். 
 
        இந்த ஆராய்ச்சியில் பங்ேகற்பᾐ தங்களின் விᾞப்பத்தின் ேபாில் தான் 
இᾞக்கிறᾐ.ேமᾤம் நீங்கள் எந்ேநரᾙம் இந்த ஆராய்ச்சியிᾢᾞந்ᾐ பின்வாங்கலாம் 
என்பைதᾜம் ெதாிவித்ᾐக் ெகாள்கிேறாம். 
 
        இந்தச் சிறப்ᾗப் பாிேசாதைனயின் ᾙᾊᾫகள் ஆராய்ச்சியின் ேபாᾐ அல்லᾐ 
ஆராய்ச்சியின் ᾙᾊவின் ேபாᾐ தங்கᾦக்கு அறிவிக்கப்பᾌம் என்பைதᾜம் ெதாிவித்ᾐக் 
ெகாள்கிேறாம் 
 
 
ஆராய்ச்சியாளர் ைகெயாப்பம்         பங்ேகற்பவர் ைகெயாப்பம் 
 
 
ேததி  
 
 
 
Appendix XI  - Copy of Informed Consent   
ஆராய்ச்சி ஒப்ᾗதல் கᾊதம் 
ஆராய்ச்சித் தைலப்ᾗ :        மனச் சிைதᾫ(schizophrenia) ேநாயாளிகளிடம் நிலᾫம் 
ᾗைகப் பழக்கத்ைதப் (nicotine dependence)பற்றிய ஆய்ᾫ  
 
  ெபயர்   :                           ேததி              : 
  வயᾐ   :                           உள்ேநாயாளி எண் : 
  பால்    :                   ஆராய்ச்சிச் ேசர்க்ைக  எண் : 
 
    இந்த ஆராய்ச்சியின் விவரங்கᾦம் அதன் ேநாக்கᾙம் எனக்கு ᾙᾨைமயாகᾫம் 
ெதளிவாகᾫம் விளக்கப் பட்டன. 
 
    எனக்கு விளக்கப் பட்ட விஷயங்கைளப் ᾗாிந்ᾐ ெகாண்ᾌ நான் எனᾐ 
சம்மதத்ைதத் தᾞகிேறன். 
 
    மனச் சிைதᾫ ேநாயாளிகளிட்ம் நிலᾫம் ᾗைகப் பழக்கத்ைதப்  பற்றிய ஆய்ᾫ என்ᾔம் 
ஆராய்ச்சியில் பங்ேகற்க நான் சம்மதம் ெதாிவிக்கின்ேறன். 
 
    இந்த ஆராய்ச்சியில் பிறர் நிர்ப்பந்தமின்றி என் ெசாந்த விᾞப்பத்தின் ேபாில் நான் 
பங்கு ெபᾠகிேறன் மற்ᾠம் நான் இந்த ஆராய்ச்சியிᾢᾞந்ᾐ எந்ேநரᾙம் விலகலாம் 
என்பைதᾜம் அதனால் எந்த பாதிப்ᾗம் ஏற்படாᾐ என்பைதᾜம் நான் ᾗாிந்ᾐ 
ெகாண்ேடன். 
 
        நான் என்ᾔைடய சுயநிைனᾫடன் மற்ᾠம் ᾙᾨ சுதந்திரத்ᾐடன் இந்த மᾞத்ᾐவ 
ஆராய்ச்சியில் என்ைனச் ேசர்த்ᾐக் ெகாள்ளச் சம்மதிக்கிேறன் 
 
                                          ைகெயாப்பம் 
 
 
Appendix XII   - Master Chart 
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